Rectal Indomethacin vs Intravenous Ketorolac
Post-ERCP Acute Pancreatitis
About this trial
This is an interventional prevention trial for Post-ERCP Acute Pancreatitis
Eligibility Criteria
Inclusion Criteria: Any patient undergoing ERCP (diagnostic or therapeutic with cannulation of the major or minor papilla) Age 6 month- 21 years old Does not meet exclusion criteria Exclusion Criteria: < 10 kg Low risk subgroup: Biliary indication with history of prior biliary sphincterotomy. High risk for bleeding (Example: Planned liver biopsy) Gastrointestinal bleeding in previous 3 days Acute pancreatitis (within 3 days) at the time of ERCP Use of NSAIDs in the previous 5 days Peptic ulcer disease Acute kidney Injury or Known Chronic Kidney Disease per KDIGO Pregnancy (Pregnancy tests are administered prior to ERCP as standard of care) Lithium therapy Allergy to ketorolac or indomethacin Organ Dysfunction or SIRS
Sites / Locations
- Cincinnati Children's Hospital Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Rectal indomethacin
IV ketorolac
Dosage based on subject's weight: >=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg
Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)